FWM
SRPT icon

Focused Wealth Management’s Sarepta Therapeutics SRPT Stock Holding History

Focused Wealth Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-400
Closed -$2K – 863
2020
Q2 		$2K Sell
400
-1,600
-80% -$218K ﹤0.01% 691
2020
Q1 		$1K Buy
+2,000
New +$229K ﹤0.01% 675

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Focused Wealth Management's SRPT Position: Q1 2024 in Review

Focused Wealth Management sold out of Sarepta Therapeutics (SRPT) in Q1 2024, closing a stake of 40 shares — an estimated $3.86K sold.

Focused Wealth Management first reported a position in SRPT in Q3 2018 and held it in 22 quarters. The position peaked at $1.48M in Q3 2018. 414 funds tracked by Wall St. Rank hold SRPT as of Q1 2024.

  • Focused Wealth Management reported no remaining Sarepta Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Focused Wealth Management sold 40 Sarepta Therapeutics shares in Q1 2024, an estimated $3.86K.
  • Focused Wealth Management first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 22 quarters.
  • Focused Wealth Management's Sarepta Therapeutics position peaked at $1.48M in Q3 2018.
  • 414 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2024.

Based on Focused Wealth Management's 13F filing for Q1 2024, filed 8 May 2024.